What does the Medicines Management team do?

The Medicines Management team is made up of Pharmacists, a Pharmacy Technician, a Dietitian and support and analytical staff who support health professionals in ensuring that patients get better, safer and more convenient care.

The team uses its wealth of knowledge and experience to provide unbiased information on medicines, supports practitioners to make the best use of medicines through advice and the development of local guides, and works with providers to ensure the right medicines are supplied at the right place.

The team provides support to health professionals directly and is unable to advise individual patients on their medicines. Your prescriber (e.g. GP) has access to your medical record and is in the best position to make prescribing decisions on your individual circumstances.

For more information, visit the “Who are the Medicines Management team?”

Formulary and Prescribing Guidelines

Medicines Management

 

Please click on the heading to view formulary, shared care guidelines and pathways for each BNF chapter.

Coronavirus (COVID-19) - Patients

Coronavirus (COVID-19) - Clinicians

Vitamin D in Care Homes

Guidance for Care Homes on the use of Vitamin D supplements obtained by the DHSC

 

Coronavirus Position Statement

Position statement for prescribing for patients abroad during Coronavirus outbreak

Prescription management during COVID-19

 

Useful Covid-19 Resources

Information around medicines use in Covid-19 is changing rapidly. Stay on top of the most recent information produced by the government and the Royal Pharmaceutical Society, using the links below:

https://www.rpharms.com/coronavirus

https://www.nice.org.uk/covid-19

https://www.gov.uk/government/collections/mhra-guidance-on-coronavirus-covid-19

 

Please note that only registered users can download the below documents:

Covid-19 Vaccine

COVID-19 primary care vaccine handling and management policy

Covid-19 Vaccine Pharmacy Communications Reference Guide

Letter from Chief Medical Officers re UK Covid-19 Vaccination Programme

Optimising the Covid-19 vaccination programme for maximum short term impact

Green Book – Covid-19

Patient Group Direction for COVID-19 Vaccines

Standard operating procedure: COVID-19 local vaccination services deployment in community settings

 

Pfizer

Specialist Pharmacy Service (SPS) Covid-19 Pfizer-BioNTech vaccine resources

Patient Group Direction for COVID 19 mRNA vaccine BNT162b2 (Pfizer BioNTech)

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

Referrals for cohort 6 16 and 17 year olds who require a Pfizer vaccination

 

AstraZeneca

Specialist Pharmacy Service (SPS) - Resources for AstraZeneca Covid-19 vaccine

Patient Group Direction for COVID-19 Vaccine AstraZeneca

National protocol for COVID-19 Vaccine AstraZeneca

Position Statement AstraZeneca Vaccine Movement

Transporting AstraZeneca COVID-19 Vaccine from PCN Designated Sites to end user locations SOP

 

Moderna

Moderna Covid 19 Vaccine Protocol

 

Covid-19 and professional advice

Security advice for pharmacies during COVID 19

COVID related professional advice

NHS Volunteer Responders information for health professionals

 

Covid-19 and services

Remote Outpatient Clinics - Medicines Supply

Responsibility for Prescribing - May 2020

Monitoring of shared care medicines during the COVID 19 pandemic

Access to Palliative Care Drugs for clinicans

Access to EOL Drugs in Primary Care during Covid-19

Essex arrangements for accessing End of Life Medicines and your role in the Re-Use of Medicines Scheme in Care Homes webinar

MSE Hospitals Group Anticoagulation Clinics

 

Covid-19 and medicines

Covid-19 - amber drugs

Ibuprofen and coronavirus (COVID 19)

Lithium and Covid-19 Guidance 

Rescue Pack Letter

Rescue packs for COPD and asthma for clinicians

Ramadan summary fasting recommendations - British Islamic Medical Association

 

Chapter 01 - Gastro-Intestinal System

Budesonide orodispersible for eosinophilic oesophagitis (NICE TA708) position statement

Infantile Colic

Infliximab (Remsima®) subcutaneous injection for treating Crohn's disease and ulcerative colitis

Electrolyte mix (St Mark's solution)

Fibrates for the management of Primary Biliary Cholangitis (PBC)

Pathway for the management of chronic constipation in adults

Proton pump inhibitor (PPI) use in paediatric patients – prescribing guidance for primary, community and secondary care

Prucalopride for chronic constipation in men

Naldemedine for treating opioid-induced constipation (NICE TA651) MSEMOC position statement

St Mark’s Solution Instructions wards

Sucralfate MSEMOC position statement 

Vedolizumab (Entyvio®) subcutaneous injection for treating Crohn's disease and ulcerative colitis

Chapter 02 - Cardiovascular System

Joint cardiovascular System Formulary (MSEMOC)

 

Atrial fibrillation anticoagulant clinical decision aid

Bempedoic acid with ezetimibe for lipid management (NICE TA694) position statement

Dapagliflozin for treating chronic HF with reduced ejection fraction (NICE TA679) position statement

Doxazosin MR MSEMOC Position statement

Entresto prescribing guidance

Entresto prescribing pathway

Heart failure diuretic flow chart

Heart failure treatment algorithm

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733) position statement

LMWH Guidance

Perindopril arginine MSEMOC Position statement

Omega 3 FAs MSEMOC Position statement

Vericiguat for treating chronic heart failure with reduced ejection fraction (NICE TA731) position statement

Vernakalant for rapid conversion AF to sinus rhythm (NICE TA675) position statement

Chapter 03 - Respiratory System

Chapter 04 - Central Nervous System

Cannabis products MSEMOC position statement

Cenobamate for treating focal onset seizures (NICE TA753) position statement

Chronic Fatigue Syndrome MSEMOC Position statement

Chronic migraine - pathway for PbR excluded drugs for preventing chronic migraine in adults

Co-proxamol MSEMOC position statement

Dosulepin

EPUT formulary and shared care guidelines

Erenumab for preventing migraine (NICE TA682) position statement

Fentanyl immediate release preparations MSEMOC position statement

Galcanezumab for preventing migraine (NICE TA659) MSEMOC position statement

Good practice for Paracetamol prescribing

Headache in adults pathway

Ketamine for chronic pain

Lidocaine plasters MSEMOC position statement

Low dose naltrexone MSEMOC position statement

Melatonin (Slenyto®) for the treatment of insomnia

Melatonin for children and adolescents

Oxycodone naloxone MSEMOC position statement

Solriamfetol for treating excessive daytime sleepiness (NICE TA758) position statement

Tramadol review guidance

Tramadol paracetamol MSEMOC position statement

Trimipramine

Chapter 05 - Infection

Chapter 06 - Endocrine System

Chapter 07 - Genito-Urinary formulary

Chapter 08 - Malignant Disease

Chapter 09 - Nutrition and Blood

Oral Nutritional Supplements Guidelines 

Adult Oral Nutritional Supplements Prescribing Guidelines

Quick reference guide to ONS prescribing in adults

Supporting Leaflets for Cows' Milk Allergy

COLOUR Cows' Milk Allergy leaflet for families

BLACK + WHITE Cows' Milk Allergy leaflet for families

Dairy free diet information for breastfeeding mothers

Milk ladder

Home challenge

Primary Care Milk Allergy Pathway

Secondary Care Milk Allergy Pathway

Infant Formula Guidelines (IFG)

Infant formula prescribing guidelines

Quick reference guide to prescribing infant formula

Vitamin and Mineral Guidelines 

Ferric maltol (Feraccru®) for the treatment of iron deficiency in adults

Probiotics MSEMOC position statement

Vitamins and minerals MSEMOC position statement

Vitamin D deficiency prescribing guidance

Vitamin D for supplementation insufficiency and maintenance doses MSEMOC position statement

Vitamin D self care leaflet

Vitamin D - guidance for care homes on the use of Vitamin D supplements obtained by the DHSC

Stopping low dose vitamin D patient letter

Multivitamins post-bariatric surgery MSEMOC position statement

Multivitamins not supported unless for actual vitamin/mineral deficiency

Vitamin B compound MSEMOC Position statement

Gluten-free Prescription Guidelines

Gluten-free foods on prescription

Thickeners for Adults with Dysphagia

A guide to prescribing thickeners for adults

Position Statements

Andexanet alfa for reversing anticoagulation (NICE TA697) position statement

Fostamatinib for treating refractory chronic ITP (NICE TA759) position statement

Sodium zirconium for treating hyperkalaemia (NICE TA599) position statement

Chapter 10 - Musculoskeletal System

Chapter 11 - Eye

Chapter 12 - Ear, Nose and Oropharynx

Chapter 13 - Skin

Acne pathway

Actinic keratoses pathway

Baricitinib for treating moderate to severe atopic dermatitis (NICE TA681) position statement

Bimekizumab for plaque psoriasis (NICE TA723) position statement

Brimonidine tartrate MSEMOC position statement

Camouflage creams MSEMOC position statement

Crisaborole for atopic dermatitis (NICE TA701) position statement

Eflornithine (Vaniqa®) cream MSEMOC position statement

Emollients prescribing guidance

Emollients for dry skin patient letter

Emollients switch to an alternative patient letter

Fungal nail infections topical treatments MSEMOC position statement

Heel balms

Minocycline for acne vulgaris

Potassium hydroxide 5% (Molludab, Mollutrex) solution MSEMOC position statement

Pigmanorm cream for the treatment of melasma

Rosacea pathway

Severe plaque psoriasis treatment pathway

Silicone sheets and gels

Sunscreen preparations MSEMOC position statement

Stopping bath and shower emollients patient letter

Therapeutic clothing MSEMOC position statement

Topical Treatment Pathway Psoriasis

Chapter 14 – Immunological Products and Vaccines

General Prescribing Guidance

End of Life Formulary

Woundcare Formulary

Traffic Light List for Prescribing

Shared Care Guidelines

Mid and South Essex Medicines Optimisation Committee (MSEMOC)

Prescribing Incentive Scheme

Prescribing Updates / Newsletters

Patient Information

Over the Counter medicines leaflets

Over the counter leaflet

Over the counter patient info sheet

Easy read over the counter leaflet

 

Changes to Co-Proxamol Prescribing

Changes to Dosulepin Prescribing

Changes to Doxazosin Prescribing

Changes to Glucosamine Prescribing

Changes to Herbal Treatment Prescribing

Changes to Homeopathy Prescribing

Changes to Immediate Release Fentanyl Prescribing

Changes to Lidocaine Plaster Prescribing

Changes to liothyronine prescribing

Changes to Lutein and Antioxidant supplements Prescribing

Changes to Omega 3 Fatty Acids Prescribing

Changes to Once Daily Tadalafil Prescribing

Changes to Perindopril Arginine Prescribing

Changes to Rubefacients Prescribing

Changes to Targinact Prescribing

Changes to Tramacet Prescribing

Changes to Travel Vaccines Prescribing

Changes to Trimipramine Prescribing

Do You Have a Dental Problem? leaflet

Freestyle Libre Q&A

Patient Letters

Practice Resources/Policies

Eclipse

National Medicine Shortages

Please note that only registered users can download the below documents:

February 2022

Supply Shortages - February 2022